<i>SOD1</i> is a synthetic lethal target in <i>PPM1D</i> -mutant leukemia cells
Linda Zhang(Baylor College of Medicine), Margaret A. Goodell(Baylor College of Medicine), Alejandra G. Martell(Baylor College of Medicine), George S. Vassiliou(Wellcome/MRC Cambridge Stem Cell Institute), Elsa Callén(National Cancer Institute), Shixia Huang, André Nussenzweig(National Institutes of Health), Lisenka E.L.M. Vissers(Radboud University Nijmegen), Katharina Wohlan(Baylor College of Medicine), Koichi Takahashi(The University of Texas MD Anderson Cancer Center), Cristian Coarfa(Baylor College of Medicine), Sandra Jansen(Radboud University Nijmegen), Étienne De Braekeleer(Wellcome Sanger Institute), Joanne I. Hsu(Harvard University), Tajhal D. Patel(Baylor College of Medicine), Rebecca Murdaugh(Baylor College of Medicine), Jamie N. Anastas(Baylor College of Medicine), Anna Guzman(Baylor College of Medicine), Ayala Tovy(Baylor College of Medicine), Hidetaka Urya(The University of Texas MD Anderson Cancer Center), Bert de Vries(Radboud University Nijmegen), Sarah M. Waldvogel(Baylor College of Medicine), Rosemary Richard(Baylor College of Medicine), Chun-Wei Chen(Baylor College of Medicine)
Cited by 2
Related Papers
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia
|Cell Reports|2016|834
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
|Nature Genetics|2020|739
Ibrutinib and Venetoclax for First-Line Treatment of CLL
|New England Journal of Medicine|2019|502
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy
|Cell stem cell|2018|423